| 21838707 |
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
Schönherr, C,
Ruuth, K,
Yamazaki, Y,
Eriksson, T,
Christensen, J,
Palmer, RH,
Hallberg, B
|
Biochem J |
2011 |
| 11110708 |
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
Bai, RY,
Ouyang, T,
Miething, C,
Morris, SW,
Peschel, C,
Duyster, J
|
Blood |
2000 |
| 23104988 |
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
Chand, D,
Yamazaki, Y,
Ruuth, K,
Schönherr, C,
Martinsson, T,
Kogner, P,
Attiyeh, EF,
Maris, J,
Morozova, O,
Marra, MA,
Ohira, M,
Nakagawara, A,
Sandström, PE,
Palmer, RH,
Hallberg, B
|
Dis Model Mech |
2013 |
| 21494621 |
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas
Cerchietti, L,
Damm-Welk, C,
Vater, I,
Klapper, W,
Harder, L,
Pott, C,
Yang, SN,
Reiter, A,
Siebert, R,
Melnick, A,
Woessmann, W
|
PLoS One |
2011 |
| 21656749 |
A novel KIF5B-ALK variant in nonsmall cell lung cancer
Wong, DW,
Leung, EL,
Wong, SK,
Tin, VP,
Sihoe, AD,
Cheng, LC,
Au, JS,
Chung, LP,
Wong, MP
|
Cancer |
2011 |
| 18923525 |
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, RE,
Sanda, T,
Hanna, M,
Fröhling, S,
Luther, W,
Zhang, J,
Ahn, Y,
Zhou, W,
London, WB,
McGrady, P,
Xue, L,
Zozulya, S,
Gregor, VE,
Webb, TR,
Gray, NS,
Gilliland, DG,
Diller, L,
Greulich, H,
Morris, SW,
Meyerson, M,
Look, AT
|
Nature |
2008 |
| 22249260 |
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
Okubo, J,
Takita, J,
Chen, Y,
Oki, K,
Nishimura, R,
Kato, M,
Sanada, M,
Hiwatari, M,
Hayashi, Y,
Igarashi, T,
Ogawa, S
|
Oncogene |
2012 |
| 22570254 |
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer
Ren, H,
Tan, ZP,
Zhu, X,
Crosby, K,
Haack, H,
Ren, JM,
Beausoleil, S,
Moritz, A,
Innocenti, G,
Rush, J,
Zhang, Y,
Zhou, XM,
Gu, TL,
Yang, YF,
Comb, MJ
|
Cancer Res |
2012 |
| 23139213 |
Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma
Cazes, A,
Louis-Brennetot, C,
Mazot, P,
Dingli, F,
Lombard, B,
Boeva, V,
Daveau, R,
Cappo, J,
Combaret, V,
Schleiermacher, G,
Jouannet, S,
Ferrand, S,
Pierron, G,
Barillot, E,
Loew, D,
Vigny, M,
Delattre, O,
Janoueix-Lerosey, I
|
Cancer Res |
2013 |
| 21415216 |
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer
Takezawa, K,
Okamoto, I,
Nishio, K,
Jänne, PA,
Nakagawa, K
|
Clin. Cancer Res. |
2011 |
| 18594010 |
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Koivunen, JP,
Mermel, C,
Zejnullahu, K,
Murphy, C,
Lifshits, E,
Holmes, AJ,
Choi, HG,
Kim, J,
Chiang, D,
Thomas, R,
Lee, J,
Richards, WG,
Sugarbaker, DJ,
Ducko, C,
Lindeman, N,
Marcoux, JP,
Engelman, JA,
Gray, NS,
Lee, C,
Meyerson, M,
Jänne, PA
|
Clin Cancer Res |
2008 |
| 18923524 |
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y,
Takita, J,
Choi, YL,
Kato, M,
Ohira, M,
Sanada, M,
Wang, L,
Soda, M,
Kikuchi, A,
Igarashi, T,
Nakagawara, A,
Hayashi, Y,
Mano, H,
Ogawa, S
|
Nature |
2008 |
